141 related articles for article (PubMed ID: 36241697)
1. Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.
Seifert R; Kersting D; Rischpler C; Sandach P; Ferdinandus J; Fendler WP; Rahbar K; Weckesser M; Umutlu L; Hanoun C; Hüttmann A; Reinhardt HC; von Tresckow B; Herrmann K; Dührsen U; Schäfers M
Leukemia; 2022 Dec; 36(12):2845-2852. PubMed ID: 36241697
[TBL] [Abstract][Full Text] [Related]
2. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.
Dührsen U; Müller S; Hertenstein B; Thomssen H; Kotzerke J; Mesters R; Berdel WE; Franzius C; Kroschinsky F; Weckesser M; Kofahl-Krause D; Bengel FM; Dürig J; Matschke J; Schmitz C; Pöppel T; Ose C; Brinkmann M; La Rosée P; Freesmeyer M; Hertel A; Höffkes HG; Behringer D; Prange-Krex G; Wilop S; Krohn T; Holzinger J; Griesshammer M; Giagounidis A; Raghavachar A; Maschmeyer G; Brink I; Bernhard H; Haberkorn U; Gaska T; Kurch L; van Assema DME; Klapper W; Hoelzer D; Geworski L; Jöckel KH; Scherag A; Bockisch A; Rekowski J; Hüttmann A;
J Clin Oncol; 2018 Jul; 36(20):2024-2034. PubMed ID: 29750632
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP.
Jeon YW; O JH; Park KS; Min GJ; Park SS; Yoon JH; Eom KS; Min CK; Cho SG
Br J Haematol; 2020 Mar; 188(6):860-871. PubMed ID: 31733125
[TBL] [Abstract][Full Text] [Related]
4. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
5. Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non-Burkitt Aggressive B-cell Lymphoma.
Cherng HJ; Sargent RL; Nasta SD; Svoboda J; Schuster SJ; Mato AR; Schrank-Hacker A; Morrissette JJD; Landsburg DJ
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):673-678. PubMed ID: 30033208
[TBL] [Abstract][Full Text] [Related]
6. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.
Persky DO; Li H; Stephens DM; Park SI; Bartlett NL; Swinnen LJ; Barr PM; Winegarden JD; Constine LS; Fitzgerald TJ; Leonard JP; Kahl BS; LeBlanc ML; Song JY; Fisher RI; Rimsza LM; Smith SM; Miller TP; Friedberg JW
J Clin Oncol; 2020 Sep; 38(26):3003-3011. PubMed ID: 32658627
[TBL] [Abstract][Full Text] [Related]
7. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
[TBL] [Abstract][Full Text] [Related]
8. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
Hüttmann A; Rekowski J; Müller SP; Hertenstein B; Franzius C; Mesters R; Weckesser M; Kroschinsky F; Kotzerke J; Ganser A; Bengel FM; La Rosée P; Freesmeyer M; Höffkes HG; Hertel A; Behringer D; Prange-Krex G; Griesshammer M; Holzinger J; Wilop S; Krohn T; Raghavachar A; Maschmeyer G; Brink I; Schroers R; Gaska T; Bernhard H; Giagounidis A; Schütte J; Dienst A; Hautzel H; Naumann R; Klein A; Hahn D; Pöpperl G; Grube M; Marienhagen J; Schwarzer A; Kurch L; Höhler T; Steiniger H; Nückel H; Südhoff T; Römer W; Brinkmann M; Ose C; Alashkar F; Schmitz C; Dürig J; Hoelzer D; Jöckel KH; Klapper W; Dührsen U
Ann Hematol; 2019 Apr; 98(4):897-907. PubMed ID: 30610279
[TBL] [Abstract][Full Text] [Related]
9. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Hertzberg M; Gandhi MK; Trotman J; Butcher B; Taper J; Johnston A; Gill D; Ho SJ; Cull G; Fay K; Chong G; Grigg A; Lewis ID; Milliken S; Renwick W; Hahn U; Filshie R; Kannourakis G; Watson AM; Warburton P; Wirth A; Seymour JF; Hofman MS; Hicks RJ;
Haematologica; 2017 Feb; 102(2):356-363. PubMed ID: 28143954
[TBL] [Abstract][Full Text] [Related]
10. Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma.
Wight J; Wai SH; Shen E; Lee ST; Berlangieri S; Fancourt T; Hawkes E; Hannah A; Leung T; Chong G
Eur J Haematol; 2021 Oct; 107(4):475-483. PubMed ID: 34240453
[TBL] [Abstract][Full Text] [Related]
11. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
Schmitz C; Rekowski J; Müller SP; Hertenstein B; Franzius C; Ganser A; Bengel FM; Kroschinsky F; Kotzerke J; La Rosée P; Freesmeyer M; Hoeffkes HG; Hertel A; Behringer D; Mesters R; Weckesser M; Mahlmann S; Haberkorn U; Martens U; Prange-Krex G; Brenner W; Giagounidis A; Moeller R; Runde V; Sandmann M; Hautzel H; Wilop S; Krohn T; Dürk H; Heike M; Alashkar F; Brinkmann M; Trenn G; Wacker D; Kreisel-Büstgens C; Bernhard H; Heil G; Larisch R; Kurch L; Jöckel KH; Hoelzer D; Klapper W; Boellaard R; Dührsen U; Hüttmann A
Hematol Oncol; 2020 Aug; 38(3):244-256. PubMed ID: 32067259
[TBL] [Abstract][Full Text] [Related]
12. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
13. Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.
Jin J; Ji D; Xia Z; Xue K; Zhang Q; Liu Y; Cao J; Hong X; Gu JJ; Guo Y; Lv F
BMC Cancer; 2022 Apr; 22(1):403. PubMed ID: 35418080
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
[TBL] [Abstract][Full Text] [Related]
15. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
16. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trial.
Dührsen U; Hüttmann A; Jöckel KH; Müller S
Leuk Lymphoma; 2009 Nov; 50(11):1757-60. PubMed ID: 19863177
[TBL] [Abstract][Full Text] [Related]
18. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma.
Herrmann K; Wieder HA; Buck AK; Schöffel M; Krause BJ; Fend F; Schuster T; Meyer zum Büschenfelde C; Wester HJ; Duyster J; Peschel C; Schwaiger M; Dechow T
Clin Cancer Res; 2007 Jun; 13(12):3552-8. PubMed ID: 17575218
[TBL] [Abstract][Full Text] [Related]
19. The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma.
Nagle SJ; Chong EA; Chekol S; Shah NN; Nasta SD; Glatstein E; Plastaras JP; Torigian DA; Schuster SJ; Svoboda J
Cancer Med; 2015 Jan; 4(1):7-15. PubMed ID: 25205600
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
